{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:57:51Z","timestamp":1781665071874,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the impact of continuing versus stopping biologic disease-modifying anti-rheumatic drugs (bDMARDs) during the perioperative period on surgical site infections (SSIs), delayed wound healing, and disease flares in patients with inflammatory arthritis (IA) undergoing elective non-orthopaedic surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of observational studies assessing the perioperative management of bDMARDs in IA patients undergoing elective non-orthopaedic surgery. Searches were conducted across seven databases and trial registries from the year 2000 onwards. Eligible studies compared outcomes in patients who continued versus stopped biologic therapy. Risk of bias was assessed using the ROBINS-I tool and due to heterogeneity data were synthesised narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight observational studies met the inclusion criteria. All studies were at moderate or serious risk of bias. Four studies compared infections with two suggesting higher infection rates in the stop biologic group. Two studies assessed delayed wound healing, both suggesting higher rates in the stop group. Disease flares were more common in patients who stopped biologics in all three of the studies reporting this outcome. No studies assessed health-related quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The available observational evidence does not demonstrate a consistent increase in postoperative infection or wound complications related to biologic continuation, however, confidence in these findings is limited by serious risk of bias and outcome heterogeneity. High-quality randomised controlled trials are needed to inform the perioperative management guidelines for IA patients undergoing elective non-orthopaedic procedures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-026-00650-y","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:14:57Z","timestamp":1777536897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative biologic use and postoperative outcomes in patients with inflammatory arthritis: a systematic review"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-2776","authenticated-orcid":false,"given":"Samantha","family":"Brady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-0900","authenticated-orcid":false,"given":"Johanna","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7920-9892","authenticated-orcid":false,"given":"Katie","family":"Carlisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-0850","authenticated-orcid":false,"given":"Joy","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1099","authenticated-orcid":false,"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-3536","authenticated-orcid":false,"given":"Catherine","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-5673","authenticated-orcid":false,"given":"Laura","family":"Mandefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-6582","authenticated-orcid":false,"given":"Kulveer","family":"Mankia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7392-8561","authenticated-orcid":false,"given":"Hemant","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-9033","authenticated-orcid":false,"given":"Andrew","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"650_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3399\/bjgp18X695705","volume":"68","author":"H Jethwa","year":"2018","unstructured":"Jethwa H, Abraham S. Biologic agents in inflammatory arthritis. Br J Gen Pract. 2018;68:204\u20135.","journal-title":"Br J Gen Pract"},{"key":"650_CR2","doi-asserted-by":"crossref","unstructured":"Singh JA, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst. Rev. 2011;CD008794.","DOI":"10.1002\/14651858.CD008794"},{"key":"650_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/rheumatology\/key207","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary. Rheumatology (Oxford). 2019;58:220\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"650_CR4","doi-asserted-by":"crossref","unstructured":"Goodman SM, et al. 2022 American college of rheumatology\/American association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res. (Hoboken) 2022:74;1399\u20131408.","DOI":"10.1002\/acr.24893"},{"key":"650_CR5","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1093\/rheumatology\/keab902","volume":"61","author":"L Uhrenholt","year":"2022","unstructured":"Uhrenholt L, et al. Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2022;61:3107\u201322.","journal-title":"Rheumatology (Oxford)"},{"key":"650_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2106\/JBJS.21.00811","volume":"104","author":"BH van Duren","year":"2022","unstructured":"van Duren BH, et al. The effect of perioperative biologic disease-modifying anti-rheumatic drugs on the risk of postoperative complications: Surgical site infection, delayed wound healing, and disease flares following orthopaedic surgical procedures. J Bone Joint Surg Am. 2022;104:1116\u201326.","journal-title":"J Bone Joint Surg Am"},{"key":"650_CR7","doi-asserted-by":"publisher","first-page":"e084997","DOI":"10.1136\/bmjopen-2024-084997","volume":"14","author":"S Brady","year":"2024","unstructured":"Brady S, et al. PERI-operative biologic DMARD management: Stoppage or COntinuation during orthoPaEdic operations (the PERISCOPE trial) - a study protocol for a pragmatic, UK multicentre, superiority randomised controlled trial with an internal pilot, economic evaluation and nested qualitative study. BMJ Open. 2024;14:e084997.","journal-title":"BMJ Open"},{"key":"650_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jdv.12997","volume":"30","author":"W Bakkour","year":"2016","unstructured":"Bakkour W, Purssell H, Chinoy H, Griffiths CEM, Warren RB. The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. J Eur Acad Dermatol Venereol. 2016;30:86\u201391.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"650_CR9","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1093\/rheumatology\/keaa291","volume":"59","author":"MM Ward","year":"2020","unstructured":"Ward MM, Dasgupta A. Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology (Oxford). 2020;59:3917\u201326.","journal-title":"Rheumatology (Oxford)"},{"key":"650_CR10","first-page":"430","volume":"25","author":"A Ruyssen-Witrand","year":"2007","unstructured":"Ruyssen-Witrand A, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25:430\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"650_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00296-014-3121-0","volume":"35","author":"Z Abou Zahr","year":"2015","unstructured":"Abou Zahr Z, Spiegelman A, Cantu M, Ng B. Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs\u2019 administrative database study. Rheumatol Int. 2015;35:265\u201372.","journal-title":"Rheumatol Int"},{"key":"650_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/annrheumdis-2019-216802","volume":"79","author":"MD George","year":"2020","unstructured":"George MD, et al. Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. Ann Rheum Dis. 2020;79:573\u201380.","journal-title":"Ann Rheum Dis"},{"key":"650_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ad.2016.08.003","volume":"108","author":"S Galiano Mej\u00edas","year":"2017","unstructured":"Galiano Mej\u00edas S, et al. Management of biologic therapy in moderate to severe psoriasis in surgical patients: Data from the Spanish Biobadaderm registry. Actas Dermosifiliogr. 2017;108:52\u20138.","journal-title":"Actas Dermosifiliogr"},{"key":"650_CR14","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/acr.22056","volume":"65","author":"S Godot","year":"2013","unstructured":"Godot S, et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken). 2013;65:1874\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"650_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/0974-8237.156044","volume":"6","author":"R Khanna","year":"2015","unstructured":"Khanna R, et al. The impact of steroids, methotrexate, and biologics on clinical and radiographic outcomes in patients with rheumatoid arthritis undergoing fusions at the craniovertebral junction. J Craniovertebr Junction Spine. 2015;6:60\u20134.","journal-title":"J Craniovertebr Junction Spine"},{"key":"650_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/BRS.0000000000003402","volume":"45","author":"C J Elia","year":"2020","unstructured":"J Elia C, et al. Impact of chronic DMARD therapy in patients with rheumatoid arthritis undergoing surgery of the craniovertebral junction: A multi-center retrospective study. Spine (Phila Pa 1976). 2020;45:930\u20136.","journal-title":"Spine (Phila Pa 1976)"},{"key":"650_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jaad.2020.03.128","volume":"85","author":"ED Nguyen","year":"2021","unstructured":"Nguyen ED, Gabel CK, Kroshinsky D. Assessing the incidence of skin and soft tissue infection in patients on biologics. J Am Acad Dermatol. 2021;85:604\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"650_CR18","first-page":"S24","volume":"75","author":"A Fabiano","year":"2014","unstructured":"Fabiano A, et al. Management of patients with psoriasis treated with biological drugs needing a surgical treatment. Drug Dev Res. 2014;75(Suppl 1):S24\u20136.","journal-title":"Drug Dev Res"},{"key":"650_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1136\/ard.2005.037762","volume":"64","author":"D Wendling","year":"2005","unstructured":"Wendling D, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64:1378\u20139.","journal-title":"Ann Rheum Dis"},{"key":"650_CR20","unstructured":"Covidence [Internet]. 2022. Available from: https:\/\/www.covidence.org. Accessed 08 Sept 2025."},{"key":"650_CR21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"650_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361.","journal-title":"Res Synth Methods"},{"key":"650_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/ojra.2019.91001","volume":"09","author":"H-H Juo","year":"2019","unstructured":"Juo H-H, Peck A, Monsell SE, Ng B. Perioperative use of methotrexate and tumor necrosis factor \u03b1 inhibitors combination therapy is not likely to increase post-operative infection rate in the national veterans health administration administrative databases. Open J Rheumatol Autoimmune Dis. 2019;09:1\u201313.","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"650_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/clinpract14010006","volume":"14","author":"A Bucataru","year":"2023","unstructured":"Bucataru A, et al. Factors contributing to surgical site infections: A comprehensive systematic review of etiology and risk factors. Clin Pract. 2023;14:52\u201368.","journal-title":"Clin Pract"},{"key":"650_CR25","doi-asserted-by":"publisher","first-page":"e83743","DOI":"10.1371\/journal.pone.0083743","volume":"8","author":"E Korol","year":"2013","unstructured":"Korol E, et al. A systematic review of risk factors associated with surgical site infections among surgical patients. PLoS ONE. 2013;8:e83743.","journal-title":"PLoS ONE"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00650-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00650-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00650-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:34:17Z","timestamp":1781663657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00650-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00650-y","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}